Jason got his undergraduate degree (B.S. Chemistry) from Trinity University in San Antonio, TX in 1995. During this time, he spent three years in the laboratories of Michael P. Doyle developing enantioselective C-H insertion reactions toward ribose architectures from prochiral diazoesters. After Trinity, Jason joined the laboratories of David A. Evans at Harvard University developing chiral mixed donor ligands for late-transition metal chemistry and later discovery and development of a novel catalytic diastereoselective anti-aldol of chiral N-acyloxazolidinones. After graduating with his Ph.D. in 2001, Jason joined the process chemistry group at Abbott Laboratories. In 2004, he left Abbott and moved to Southern California to join a newly formed process chemistry and catalysis group at Amgen. He assumed various roles of increasing responsibility leading cross-functional teams in both early and late chemical development and CMC. Currently, Jason is the global head of process chemistry at Sanofi (based in Cambridge, US). He leads a team of scientists who design innovative chemical processes to transition molecules from discovery to launch. This includes a dedicated biocatalysis team focused on achieving Sanofi’s ecodesign ambition. Jason has been in the industry over 24 years and has led teams in multiple aspects of CMC development in synthetics and biologics. Jason has authored/co-authored over 60 peer reviewed publications (H-index of 31), three book chapters and twenty-one patents. He is the recipient of the American Chemical Society’s Young Investigator Award in 2012. Jason also serves on the board of Trinity University Science Board of Advisors as well as leading multiple project teams with external parties such as the Enabling Technologies Consortia, National Science Foundation SusChem Advisory Board and on the Round Table on Catalysis.

‍